No Data
No Data
Hong Kong stock changes丨Collumbotai Bio-B once rose more than 11% to a record high, and the main products were approved by the FDA for Phase 2 testing
Glonghui, May 6 | Columbotai Bio-B (6990.HK) rose by more than 11% in the afternoon, reaching a new high listing price of HK$182.2, with a total market value of nearly HK$40 billion. The company's main product, A400 (EP0031) (rearrangement during transfection (RET) small molecule kinase inhibitor program, also known as KL590586 or EP0031), was approved by the US Food and Drug Administration (FDA) for Phase 2 clinical development. A400 (EP0031) is a second-generation selective RET inhibitor (SRI) that fuses and syncs common RET genes
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%
The US Food and Drug Administration (FDA) has greenlit Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) drug A400 to proceed to Phase 2 clinical trials, according to a Friday filing on the Hong Ko
The main product A400 (EP0031) of Colombotai Bio-B (06990.HK) was approved by the US Food and Drug Administration to begin phase 2 testing
Gelonghui, May 3 | Columbotai Bio-B (06990.HK) announced that the company's main product, A400 (EP0031) (rearrangement during transfection (RET) small molecule kinase inhibitor project, also known as KL590586 or EP0031), was approved by the US Food and Drug Administration (FDA) to enter phase 2 clinical development. A400 (EP0031) is a second-generation selective RET inhibitor (SRI) and has broad activity against common RET gene fusions and mutations. In March 2021, the company became an international drug development company headquartered in the United Kingdom
This week's bullish stocks in Hong Kong | AI models are in the spotlight! Shangtang's stock price doubled this week; Kewang stocks took the lead, and Kuaishou rose more than 27% weekly
The volume of the three major indices surged this week, and the “beef flavor” is getting stronger. The Hang Seng Index rose more than 13% during the week, while the Hang Seng Index and the State-owned Enterprises Index both rose for five consecutive days.
Changes in Hong Kong stocks | Collumbotai Biotech (06990) rose more than 6%, thanks to MSD's sharp rise in revenue in 23, SKB264 is expected to become a major ADC product with significant benefits for pan-cancer
The Zhitong Finance App learned that Columbite Biotech (06990) rose by more than 6% and rose 6.04% at press time to HK$163.3, with a turnover of HK$2002 million. In terms of performance, the company released its first annual report since listing on March 25. In 2023, the company achieved operating income of 1,540 billion yuan, a year-on-year increase of 91.6%; loss during the year was 574 million yuan, a year-on-year decrease of 6.8%; the adjusted loss amount for the year was 451 million yuan, a year-on-year decrease of 24.4%. According to reports, there are currently 7 products in the process of cooperation between Colombotech and MSD. Based on the above cooperation,
Changes in Hong Kong stocks | Collumbotai Biotech (06990) rose more than 6%. SKB-264 lung cancer data is impressive, and many key developments have been made at home and abroad
The Zhitong Finance App learned that Columbite Biotech (06990) rose by more than 6%. As of press release, it had risen 6.09% to HK$148, with a turnover of HK$29.8515 million. According to the news, Guolian Securities pointed out that at the 2024 AACR conference, the SKB-264 lung cancer data presented by Columbotai was impressive, showing the potential for treating a wide range of tumors. Colombotech SKB264 is currently undergoing phase II and phase III clinical trials of single drugs/combinations for multiple cancer types around the world, and is expected to become a major ADC product with significant benefits for pan-cancer types. The bank pointed out that overseas, MSD launched seven global projects
No Data